Atlas Trials

TJ Biopharma Co., Ltd.

20 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch TJ Biopharma Co., Ltd.

RecordFirmDate
A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors (NCT07715747)TJ Biopharma Co., Ltd.2026-08-21
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis (NCT07453004)TJ Biopharma Co., Ltd.2026-03-26
A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in China (NCT07300436)TJ Biopharma Co., Ltd.2026-01-04
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) (NCT07208058)TJ Biopharma Co., Ltd.2025-11-21
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (NCT07005336)TJ Biopharma Co., Ltd.2025-01-09
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (NCT06984588)TJ Biopharma Co., Ltd.2024-03-28
Study of Felzartamab in Healthy Adult Subjects (NCT06285201)TJ Biopharma Co., Ltd.2024-03-27
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors (NCT05338580)TJ Biopharma Co., Ltd.2023-12-31
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS)) (NCT07034209)TJ Biopharma Co., Ltd.2023-04-07
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) (NCT05709093)TJ Biopharma Co., Ltd.2023-03-30
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor (NCT05148533)TJ Biopharma Co., Ltd.2021-12-30
A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus (NCT05140824)TJ Biopharma Co., Ltd.2021-12-30
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors (NCT05145907)TJ Biopharma Co., Ltd.2021-12-22
A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency (NCT04633057)TJ Biopharma Co., Ltd.2021-01-25
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) (NCT04600817)TJ Biopharma Co., Ltd.2020-12-31
A Phase I/II Study of TJ004309 for Advanced Solid Tumor (NCT04322006)TJ Biopharma Co., Ltd.2020-05-09
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04202003)TJ Biopharma Co., Ltd.2020-03-25
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03952091)TJ Biopharma Co., Ltd.2019-03-27
Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors (NCT04001075)TJ Biopharma Co., Ltd.2019-02-25
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03860038)TJ Biopharma Co., Ltd.2019-01-28

Track TJ Biopharma Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.